上皮成長因子受容体(EGFR)阻害剤の世界市場2024~2028

■ 英語タイトル:Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market 2024-2028

調査会社Technavio社が発行したリサーチレポート(データ管理コード:IRTNTR72701-23)■ 発行会社/調査会社:Technavio
■ 商品コード:IRTNTR72701-23
■ 発行日:2023年10月4日
■ 調査対象地域:北米、ヨーロッパ、アジア、その他地域
■ 産業分野:医療
■ ページ数:約120
■ レポート言語:英語
■ レポート形式:PDF
■ 納品方式:Eメール(受注後24時間以内)
■ 販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥380,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥608,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能)
Technavio社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[上皮成長因子受容体(EGFR)阻害剤の世界市場2024~2028]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

上皮成長因子受容体(EGFR)阻害剤の世界市場 2024-2028上皮成長因子受容体(EGFR)阻害剤市場は、2023年から2028年にかけて67億5,000万米ドルの成長が予測され、予測期間中のCAGRは8.6%で加速すると予測されています。当レポートでは、上皮成長因子受容体(EGFR)阻害剤市場について、市場規模や予測、動向、成長促進要因、課題などの全体的な分析に加え、約25のベンダーを網羅したベンダー分析も掲載しています。
当レポートでは、現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供します。市場は、主要ながん適応症の有病率の上昇、個別化医療に対する認識と導入の増加、技術と研究の進歩によって牽引されています。

Technavio社の上皮成長因子受容体(EGFR)阻害剤市場は以下のようにセグメント化されています。
流通チャネル別
- 小売薬局
- 病院薬局
- オンライン薬局

適応症別
- 肺がん
- 大腸がん
- 乳がん
- その他

地域別
- 北米
- ヨーロッパ
- アジア
- その他の地域(ROW)

本調査では、今後数年間における上皮成長因子受容体(EGFR)阻害剤市場の成長を促進する主な理由の一つとして、様々な種類の癌の治療に関する研究分野の増加を挙げています。また、医薬品パイプラインの増加や償還プログラムの増加は、市場の大きな需要につながるでしょう。

本レポートでは、上皮成長因子受容体(EGFR)阻害剤市場について、以下の分野をカバーしています。
- 上皮成長因子受容体(EGFR)阻害剤市場規模
- 上皮成長因子受容体(EGFR)阻害剤市場予測
- 上皮成長因子受容体(EGFR)阻害剤市場の産業分析

本レポートでは、上皮成長因子受容体(EGFR)阻害剤市場の主要ベンダーの詳細な分析を提供しています。主要ベンダーには、Amgen Inc., ASSERTIO HOLDINGS INC., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Checkpoint Therapeutics Inc., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Hansoh Pharmaceutical Group Co. Ltd., hutchison medipharma ltd., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Johnson and Johnson, Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Puma Biotechnology Inc., Takeda Pharmaceutical Co. Ltd., Apollomics Inc., CULLINAN ONCOLOGY INC., and Lutris Pharma.などがあります。また、上皮成長因子受容体(EGFR)阻害剤市場の分析レポートには、市場成長に影響を与える今後の動向や課題に関する情報も含まれています。これは、企業が戦略を立て、来るべき成長機会をすべて活用するのに役立つものです。

本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報を客観的に組み合わせて実施しました。当レポートでは、主要ベンダーの分析に加え、包括的な市場とベンダーの状況を掲載しています。
当調査会社は、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数の情報源からのデータを調査、統合、総括する方法で、市場の詳細な姿を提示しています。また、主要な業界インフルエンサーを特定することで、市場の様々な側面を提示しています。提示されるデータは包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、質的・量的調査を用いた綿密なベンダー選定方法と分析を提供します。

1 エグゼクティブサマリー
2 市場状況
3 市場規模
4 過去の市場規模
5 ファイブフォース分析
6 上皮成長因子受容体(EGFR)阻害剤の世界市場:流通チャネル別市場分析
7 上皮成長因子受容体(EGFR)阻害剤の世界市場:適応症別市場分析
8 顧客状況
9 地理的背景
10 推進要因・課題・動向
11 企業状況
12 企業分析
13 付録

世界の市場調査レポート販売サイト(H&Iグローバルリサーチ株式会社運営)
*** レポート目次(コンテンツ)***

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market By Geographical Landscape
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Distribution Channel
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Indication
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2023
o 3.4 Market outlook: Forecast for 2023-2028
o Exhibit 14: Chart on Global – Market size and forecast 2023-2028 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2023-2028 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
• 4 Historic Market Size
o 4.1 Global epidermal growth factor receptor (EGFR) inhibitors market 2018 – 2022
o Exhibit 18: Historic Market Size – Data Table on global epidermal growth factor receptor (egfr) inhibitors market 2018 – 2022 ($ million)
o 4.2 Distribution Channel Segment Analysis 2018 – 2022
o Exhibit 19: Historic Market Size – Distribution Channel Segment 2018 – 2022 ($ million)
o 4.3 Indication Segment Analysis 2018 – 2022
o Exhibit 20: Historic Market Size – Indication Segment 2018 – 2022 ($ million)
o 4.4 Geography Segment Analysis 2018 – 2022
o Exhibit 21: Historic Market Size – Geography Segment 2018 – 2022 ($ million)
o 4.5 Country Segment Analysis 2018 – 2022
o Exhibit 22: Historic Market Size – Country Segment 2018 – 2022 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2023 and 2028
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2023 and 2028
• 6 Market Segmentation by Distribution Channel
o 6.1 Market segments
o Exhibit 30: Chart on Distribution Channel – Market share 2023-2028 (%)
o Exhibit 31: Data Table on Distribution Channel – Market share 2023-2028 (%)
o 6.2 Comparison by Distribution Channel
o Exhibit 32: Chart on Comparison by Distribution Channel
o Exhibit 33: Data Table on Comparison by Distribution Channel
o 6.3 Retail pharmacies – Market size and forecast 2023-2028
o Exhibit 34: Chart on Retail pharmacies – Market size and forecast 2023-2028 ($ million)
o Exhibit 35: Data Table on Retail pharmacies – Market size and forecast 2023-2028 ($ million)
o Exhibit 36: Chart on Retail pharmacies – Year-over-year growth 2023-2028 (%)
o Exhibit 37: Data Table on Retail pharmacies – Year-over-year growth 2023-2028 (%)
o 6.4 Hospital pharmacies – Market size and forecast 2023-2028
o Exhibit 38: Chart on Hospital pharmacies – Market size and forecast 2023-2028 ($ million)
o Exhibit 39: Data Table on Hospital pharmacies – Market size and forecast 2023-2028 ($ million)
o Exhibit 40: Chart on Hospital pharmacies – Year-over-year growth 2023-2028 (%)
o Exhibit 41: Data Table on Hospital pharmacies – Year-over-year growth 2023-2028 (%)
o 6.5 Online pharmacies – Market size and forecast 2023-2028
o Exhibit 42: Chart on Online pharmacies – Market size and forecast 2023-2028 ($ million)
o Exhibit 43: Data Table on Online pharmacies – Market size and forecast 2023-2028 ($ million)
o Exhibit 44: Chart on Online pharmacies – Year-over-year growth 2023-2028 (%)
o Exhibit 45: Data Table on Online pharmacies – Year-over-year growth 2023-2028 (%)
o 6.6 Market opportunity by Distribution Channel
o Exhibit 46: Market opportunity by Distribution Channel ($ million)
o Exhibit 47: Data Table on Market opportunity by Distribution Channel ($ million)
• 7 Market Segmentation by Indication
o 7.1 Market segments
o Exhibit 48: Chart on Indication – Market share 2023-2028 (%)
o Exhibit 49: Data Table on Indication – Market share 2023-2028 (%)
o 7.2 Comparison by Indication
o Exhibit 50: Chart on Comparison by Indication
o Exhibit 51: Data Table on Comparison by Indication
o 7.3 Lung cancer – Market size and forecast 2023-2028
o Exhibit 52: Chart on Lung cancer – Market size and forecast 2023-2028 ($ million)
o Exhibit 53: Data Table on Lung cancer – Market size and forecast 2023-2028 ($ million)
o Exhibit 54: Chart on Lung cancer – Year-over-year growth 2023-2028 (%)
o Exhibit 55: Data Table on Lung cancer – Year-over-year growth 2023-2028 (%)
o 7.4 Colorectal cancer – Market size and forecast 2023-2028
o Exhibit 56: Chart on Colorectal cancer – Market size and forecast 2023-2028 ($ million)
o Exhibit 57: Data Table on Colorectal cancer – Market size and forecast 2023-2028 ($ million)
o Exhibit 58: Chart on Colorectal cancer – Year-over-year growth 2023-2028 (%)
o Exhibit 59: Data Table on Colorectal cancer – Year-over-year growth 2023-2028 (%)
o 7.5 Breast cancer – Market size and forecast 2023-2028
o Exhibit 60: Chart on Breast cancer – Market size and forecast 2023-2028 ($ million)
o Exhibit 61: Data Table on Breast cancer – Market size and forecast 2023-2028 ($ million)
o Exhibit 62: Chart on Breast cancer – Year-over-year growth 2023-2028 (%)
o Exhibit 63: Data Table on Breast cancer – Year-over-year growth 2023-2028 (%)
o 7.6 Others – Market size and forecast 2023-2028
o Exhibit 64: Chart on Others – Market size and forecast 2023-2028 ($ million)
o Exhibit 65: Data Table on Others – Market size and forecast 2023-2028 ($ million)
o Exhibit 66: Chart on Others – Year-over-year growth 2023-2028 (%)
o Exhibit 67: Data Table on Others – Year-over-year growth 2023-2028 (%)
o 7.7 Market opportunity by Indication
o Exhibit 68: Market opportunity by Indication ($ million)
o Exhibit 69: Data Table on Market opportunity by Indication ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 71: Chart on Market share By Geographical Landscape 2023-2028 (%)
o Exhibit 72: Data Table on Market share By Geographical Landscape 2023-2028 (%)
o 9.2 Geographic comparison
o Exhibit 73: Chart on Geographic comparison
o Exhibit 74: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2023-2028
o Exhibit 75: Chart on North America – Market size and forecast 2023-2028 ($ million)
o Exhibit 76: Data Table on North America – Market size and forecast 2023-2028 ($ million)
o Exhibit 77: Chart on North America – Year-over-year growth 2023-2028 (%)
o Exhibit 78: Data Table on North America – Year-over-year growth 2023-2028 (%)
o 9.4 Europe – Market size and forecast 2023-2028
o Exhibit 79: Chart on Europe – Market size and forecast 2023-2028 ($ million)
o Exhibit 80: Data Table on Europe – Market size and forecast 2023-2028 ($ million)
o Exhibit 81: Chart on Europe – Year-over-year growth 2023-2028 (%)
o Exhibit 82: Data Table on Europe – Year-over-year growth 2023-2028 (%)
o 9.5 Asia – Market size and forecast 2023-2028
o Exhibit 83: Chart on Asia – Market size and forecast 2023-2028 ($ million)
o Exhibit 84: Data Table on Asia – Market size and forecast 2023-2028 ($ million)
o Exhibit 85: Chart on Asia – Year-over-year growth 2023-2028 (%)
o Exhibit 86: Data Table on Asia – Year-over-year growth 2023-2028 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2023-2028
o Exhibit 87: Chart on Rest of World (ROW) – Market size and forecast 2023-2028 ($ million)
o Exhibit 88: Data Table on Rest of World (ROW) – Market size and forecast 2023-2028 ($ million)
o Exhibit 89: Chart on Rest of World (ROW) – Year-over-year growth 2023-2028 (%)
o Exhibit 90: Data Table on Rest of World (ROW) – Year-over-year growth 2023-2028 (%)
o 9.7 US – Market size and forecast 2023-2028
o Exhibit 91: Chart on US – Market size and forecast 2023-2028 ($ million)
o Exhibit 92: Data Table on US – Market size and forecast 2023-2028 ($ million)
o Exhibit 93: Chart on US – Year-over-year growth 2023-2028 (%)
o Exhibit 94: Data Table on US – Year-over-year growth 2023-2028 (%)
o 9.8 Germany – Market size and forecast 2023-2028
o Exhibit 95: Chart on Germany – Market size and forecast 2023-2028 ($ million)
o Exhibit 96: Data Table on Germany – Market size and forecast 2023-2028 ($ million)
o Exhibit 97: Chart on Germany – Year-over-year growth 2023-2028 (%)
o Exhibit 98: Data Table on Germany – Year-over-year growth 2023-2028 (%)
o 9.9 UK – Market size and forecast 2023-2028
o Exhibit 99: Chart on UK – Market size and forecast 2023-2028 ($ million)
o Exhibit 100: Data Table on UK – Market size and forecast 2023-2028 ($ million)
o Exhibit 101: Chart on UK – Year-over-year growth 2023-2028 (%)
o Exhibit 102: Data Table on UK – Year-over-year growth 2023-2028 (%)
o 9.10 China – Market size and forecast 2023-2028
o Exhibit 103: Chart on China – Market size and forecast 2023-2028 ($ million)
o Exhibit 104: Data Table on China – Market size and forecast 2023-2028 ($ million)
o Exhibit 105: Chart on China – Year-over-year growth 2023-2028 (%)
o Exhibit 106: Data Table on China – Year-over-year growth 2023-2028 (%)
o 9.11 Canada – Market size and forecast 2023-2028
o Exhibit 107: Chart on Canada – Market size and forecast 2023-2028 ($ million)
o Exhibit 108: Data Table on Canada – Market size and forecast 2023-2028 ($ million)
o Exhibit 109: Chart on Canada – Year-over-year growth 2023-2028 (%)
o Exhibit 110: Data Table on Canada – Year-over-year growth 2023-2028 (%)
o 9.12 Market opportunity By Geographical Landscape
o Exhibit 111: Market opportunity By Geographical Landscape ($ million)
o Exhibit 112: Data Tables on Market opportunity By Geographical Landscape ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 113: Impact of drivers and challenges in 2023 and 2028
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 115: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 116: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 117: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 118: Matrix on vendor position and classification
o 12.3 Amgen Inc.
o Exhibit 119: Amgen Inc. – Overview
o Exhibit 120: Amgen Inc. – Product / Service
o Exhibit 121: Amgen Inc. – Key offerings
o 12.4 Apollomics Inc.
o Exhibit 122: Apollomics Inc. – Overview
o Exhibit 123: Apollomics Inc. – Product / Service
o Exhibit 124: Apollomics Inc. – Key news
o Exhibit 125: Apollomics Inc. – Key offerings
o 12.5 AstraZeneca Plc
o Exhibit 126: AstraZeneca Plc – Overview
o Exhibit 127: AstraZeneca Plc – Product / Service
o Exhibit 128: AstraZeneca Plc – Key news
o Exhibit 129: AstraZeneca Plc – Key offerings
o 12.6 Boehringer Ingelheim International GmbH
o Exhibit 130: Boehringer Ingelheim International GmbH – Overview
o Exhibit 131: Boehringer Ingelheim International GmbH – Business segments
o Exhibit 132: Boehringer Ingelheim International GmbH – Key news
o Exhibit 133: Boehringer Ingelheim International GmbH – Key offerings
o Exhibit 134: Boehringer Ingelheim International GmbH – Segment focus
o 12.7 Bristol Myers Squibb Co.
o Exhibit 135: Bristol Myers Squibb Co. – Overview
o Exhibit 136: Bristol Myers Squibb Co. – Product / Service
o Exhibit 137: Bristol Myers Squibb Co. – Key news
o Exhibit 138: Bristol Myers Squibb Co. – Key offerings
o 12.8 Checkpoint Therapeutics Inc.
o Exhibit 139: Checkpoint Therapeutics Inc. – Overview
o Exhibit 140: Checkpoint Therapeutics Inc. – Product / Service
o Exhibit 141: Checkpoint Therapeutics Inc. – Key offerings
o 12.9 Eli Lilly and Co.
o Exhibit 142: Eli Lilly and Co. – Overview
o Exhibit 143: Eli Lilly and Co. – Product / Service
o Exhibit 144: Eli Lilly and Co. – Key news
o Exhibit 145: Eli Lilly and Co. – Key offerings
o 12.10 F. Hoffmann La Roche Ltd.
o Exhibit 146: F. Hoffmann La Roche Ltd. – Overview
o Exhibit 147: F. Hoffmann La Roche Ltd. – Business segments
o Exhibit 148: F. Hoffmann La Roche Ltd. – Key news
o Exhibit 149: F. Hoffmann La Roche Ltd. – Key offerings
o Exhibit 150: F. Hoffmann La Roche Ltd. – Segment focus
o 12.11 Jiangsu Hengrui Pharmaceuticals Co. Ltd.
o Exhibit 151: Jiangsu Hengrui Pharmaceuticals Co. Ltd. – Overview
o Exhibit 152: Jiangsu Hengrui Pharmaceuticals Co. Ltd. – Product / Service
o Exhibit 153: Jiangsu Hengrui Pharmaceuticals Co. Ltd. – Key offerings
o 12.12 Johnson and Johnson
o Exhibit 154: Johnson and Johnson – Overview
o Exhibit 155: Johnson and Johnson – Business segments
o Exhibit 156: Johnson and Johnson – Key news
o Exhibit 157: Johnson and Johnson – Key offerings
o Exhibit 158: Johnson and Johnson – Segment focus
o 12.13 Novartis AG
o Exhibit 159: Novartis AG – Overview
o Exhibit 160: Novartis AG – Business segments
o Exhibit 161: Novartis AG – Key offerings
o Exhibit 162: Novartis AG – Segment focus
o 12.14 Otsuka Holdings Co. Ltd.
o Exhibit 163: Otsuka Holdings Co. Ltd. – Overview
o Exhibit 164: Otsuka Holdings Co. Ltd. – Business segments
o Exhibit 165: Otsuka Holdings Co. Ltd. – Key offerings
o Exhibit 166: Otsuka Holdings Co. Ltd. – Segment focus
o 12.15 Pfizer Inc.
o Exhibit 167: Pfizer Inc. – Overview
o Exhibit 168: Pfizer Inc. – Product / Service
o Exhibit 169: Pfizer Inc. – Key news
o Exhibit 170: Pfizer Inc. – Key offerings
o 12.16 Puma Biotechnology Inc.
o Exhibit 171: Puma Biotechnology Inc. – Overview
o Exhibit 172: Puma Biotechnology Inc. – Product / Service
o Exhibit 173: Puma Biotechnology Inc. – Key offerings
o 12.17 Takeda Pharmaceutical Co. Ltd.
o Exhibit 174: Takeda Pharmaceutical Co. Ltd. – Overview
o Exhibit 175: Takeda Pharmaceutical Co. Ltd. – Product / Service
o Exhibit 176: Takeda Pharmaceutical Co. Ltd. – Key news
o Exhibit 177: Takeda Pharmaceutical Co. Ltd. – Key offerings
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 178: Inclusions checklist
o Exhibit 179: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 180: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 181: Research methodology
o Exhibit 182: Validation techniques employed for market sizing
o Exhibit 183: Information sources
o 13.5 List of abbreviations
o Exhibit 184: List of abbreviations

Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market By Geographical Landscape
Exhibits5: Executive Summary – Chart on Market Segmentation by Distribution Channel
Exhibits6: Executive Summary – Chart on Market Segmentation by Indication
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2023-2028 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2023-2028 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits18: Historic Market Size – Data Table on global epidermal growth factor receptor (egfr) inhibitors market 2018 – 2022 ($ million)
Exhibits19: Historic Market Size – Distribution Channel Segment 2018 – 2022 ($ million)
Exhibits20: Historic Market Size – Indication Segment 2018 – 2022 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2018 – 2022 ($ million)
Exhibits22: Historic Market Size – Country Segment 2018 – 2022 ($ million)
Exhibits23: Five forces analysis – Comparison between 2023 and 2028
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
Exhibits26: Threat of new entrants – Impact of key factors in 2023 and 2028
Exhibits27: Threat of substitutes – Impact of key factors in 2023 and 2028
Exhibits28: Threat of rivalry – Impact of key factors in 2023 and 2028
Exhibits29: Chart on Market condition – Five forces 2023 and 2028
Exhibits30: Chart on Distribution Channel – Market share 2023-2028 (%)
Exhibits31: Data Table on Distribution Channel – Market share 2023-2028 (%)
Exhibits32: Chart on Comparison by Distribution Channel
Exhibits33: Data Table on Comparison by Distribution Channel
Exhibits34: Chart on Retail pharmacies – Market size and forecast 2023-2028 ($ million)
Exhibits35: Data Table on Retail pharmacies – Market size and forecast 2023-2028 ($ million)
Exhibits36: Chart on Retail pharmacies – Year-over-year growth 2023-2028 (%)
Exhibits37: Data Table on Retail pharmacies – Year-over-year growth 2023-2028 (%)
Exhibits38: Chart on Hospital pharmacies – Market size and forecast 2023-2028 ($ million)
Exhibits39: Data Table on Hospital pharmacies – Market size and forecast 2023-2028 ($ million)
Exhibits40: Chart on Hospital pharmacies – Year-over-year growth 2023-2028 (%)
Exhibits41: Data Table on Hospital pharmacies – Year-over-year growth 2023-2028 (%)
Exhibits42: Chart on Online pharmacies – Market size and forecast 2023-2028 ($ million)
Exhibits43: Data Table on Online pharmacies – Market size and forecast 2023-2028 ($ million)
Exhibits44: Chart on Online pharmacies – Year-over-year growth 2023-2028 (%)
Exhibits45: Data Table on Online pharmacies – Year-over-year growth 2023-2028 (%)
Exhibits46: Market opportunity by Distribution Channel ($ million)
Exhibits47: Data Table on Market opportunity by Distribution Channel ($ million)
Exhibits48: Chart on Indication – Market share 2023-2028 (%)
Exhibits49: Data Table on Indication – Market share 2023-2028 (%)
Exhibits50: Chart on Comparison by Indication
Exhibits51: Data Table on Comparison by Indication
Exhibits52: Chart on Lung cancer – Market size and forecast 2023-2028 ($ million)
Exhibits53: Data Table on Lung cancer – Market size and forecast 2023-2028 ($ million)
Exhibits54: Chart on Lung cancer – Year-over-year growth 2023-2028 (%)
Exhibits55: Data Table on Lung cancer – Year-over-year growth 2023-2028 (%)
Exhibits56: Chart on Colorectal cancer – Market size and forecast 2023-2028 ($ million)
Exhibits57: Data Table on Colorectal cancer – Market size and forecast 2023-2028 ($ million)
Exhibits58: Chart on Colorectal cancer – Year-over-year growth 2023-2028 (%)
Exhibits59: Data Table on Colorectal cancer – Year-over-year growth 2023-2028 (%)
Exhibits60: Chart on Breast cancer – Market size and forecast 2023-2028 ($ million)
Exhibits61: Data Table on Breast cancer – Market size and forecast 2023-2028 ($ million)
Exhibits62: Chart on Breast cancer – Year-over-year growth 2023-2028 (%)
Exhibits63: Data Table on Breast cancer – Year-over-year growth 2023-2028 (%)
Exhibits64: Chart on Others – Market size and forecast 2023-2028 ($ million)
Exhibits65: Data Table on Others – Market size and forecast 2023-2028 ($ million)
Exhibits66: Chart on Others – Year-over-year growth 2023-2028 (%)
Exhibits67: Data Table on Others – Year-over-year growth 2023-2028 (%)
Exhibits68: Market opportunity by Indication ($ million)
Exhibits69: Data Table on Market opportunity by Indication ($ million)
Exhibits70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits71: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibits72: Data Table on Market share By Geographical Landscape 2023-2028 (%)
Exhibits73: Chart on Geographic comparison
Exhibits74: Data Table on Geographic comparison
Exhibits75: Chart on North America – Market size and forecast 2023-2028 ($ million)
Exhibits76: Data Table on North America – Market size and forecast 2023-2028 ($ million)
Exhibits77: Chart on North America – Year-over-year growth 2023-2028 (%)
Exhibits78: Data Table on North America – Year-over-year growth 2023-2028 (%)
Exhibits79: Chart on Europe – Market size and forecast 2023-2028 ($ million)
Exhibits80: Data Table on Europe – Market size and forecast 2023-2028 ($ million)
Exhibits81: Chart on Europe – Year-over-year growth 2023-2028 (%)
Exhibits82: Data Table on Europe – Year-over-year growth 2023-2028 (%)
Exhibits83: Chart on Asia – Market size and forecast 2023-2028 ($ million)
Exhibits84: Data Table on Asia – Market size and forecast 2023-2028 ($ million)
Exhibits85: Chart on Asia – Year-over-year growth 2023-2028 (%)
Exhibits86: Data Table on Asia – Year-over-year growth 2023-2028 (%)
Exhibits87: Chart on Rest of World (ROW) – Market size and forecast 2023-2028 ($ million)
Exhibits88: Data Table on Rest of World (ROW) – Market size and forecast 2023-2028 ($ million)
Exhibits89: Chart on Rest of World (ROW) – Year-over-year growth 2023-2028 (%)
Exhibits90: Data Table on Rest of World (ROW) – Year-over-year growth 2023-2028 (%)
Exhibits91: Chart on US – Market size and forecast 2023-2028 ($ million)
Exhibits92: Data Table on US – Market size and forecast 2023-2028 ($ million)
Exhibits93: Chart on US – Year-over-year growth 2023-2028 (%)
Exhibits94: Data Table on US – Year-over-year growth 2023-2028 (%)
Exhibits95: Chart on Germany – Market size and forecast 2023-2028 ($ million)
Exhibits96: Data Table on Germany – Market size and forecast 2023-2028 ($ million)
Exhibits97: Chart on Germany – Year-over-year growth 2023-2028 (%)
Exhibits98: Data Table on Germany – Year-over-year growth 2023-2028 (%)
Exhibits99: Chart on UK – Market size and forecast 2023-2028 ($ million)
Exhibits100: Data Table on UK – Market size and forecast 2023-2028 ($ million)
Exhibits101: Chart on UK – Year-over-year growth 2023-2028 (%)
Exhibits102: Data Table on UK – Year-over-year growth 2023-2028 (%)
Exhibits103: Chart on China – Market size and forecast 2023-2028 ($ million)
Exhibits104: Data Table on China – Market size and forecast 2023-2028 ($ million)
Exhibits105: Chart on China – Year-over-year growth 2023-2028 (%)
Exhibits106: Data Table on China – Year-over-year growth 2023-2028 (%)
Exhibits107: Chart on Canada – Market size and forecast 2023-2028 ($ million)
Exhibits108: Data Table on Canada – Market size and forecast 2023-2028 ($ million)
Exhibits109: Chart on Canada – Year-over-year growth 2023-2028 (%)
Exhibits110: Data Table on Canada – Year-over-year growth 2023-2028 (%)
Exhibits111: Market opportunity By Geographical Landscape ($ million)
Exhibits112: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits113: Impact of drivers and challenges in 2023 and 2028
Exhibits114: Overview on Criticality of inputs and Factors of differentiation
Exhibits115: Overview on factors of disruption
Exhibits116: Impact of key risks on business
Exhibits117: Vendors covered
Exhibits118: Matrix on vendor position and classification
Exhibits119: Amgen Inc. – Overview
Exhibits120: Amgen Inc. – Product / Service
Exhibits121: Amgen Inc. – Key offerings
Exhibits122: Apollomics Inc. – Overview
Exhibits123: Apollomics Inc. – Product / Service
Exhibits124: Apollomics Inc. – Key news
Exhibits125: Apollomics Inc. – Key offerings
Exhibits126: AstraZeneca Plc – Overview
Exhibits127: AstraZeneca Plc – Product / Service
Exhibits128: AstraZeneca Plc – Key news
Exhibits129: AstraZeneca Plc – Key offerings
Exhibits130: Boehringer Ingelheim International GmbH – Overview
Exhibits131: Boehringer Ingelheim International GmbH – Business segments
Exhibits132: Boehringer Ingelheim International GmbH – Key news
Exhibits133: Boehringer Ingelheim International GmbH – Key offerings
Exhibits134: Boehringer Ingelheim International GmbH – Segment focus
Exhibits135: Bristol Myers Squibb Co. – Overview
Exhibits136: Bristol Myers Squibb Co. – Product / Service
Exhibits137: Bristol Myers Squibb Co. – Key news
Exhibits138: Bristol Myers Squibb Co. – Key offerings
Exhibits139: Checkpoint Therapeutics Inc. – Overview
Exhibits140: Checkpoint Therapeutics Inc. – Product / Service
Exhibits141: Checkpoint Therapeutics Inc. – Key offerings
Exhibits142: Eli Lilly and Co. – Overview
Exhibits143: Eli Lilly and Co. – Product / Service
Exhibits144: Eli Lilly and Co. – Key news
Exhibits145: Eli Lilly and Co. – Key offerings
Exhibits146: F. Hoffmann La Roche Ltd. – Overview
Exhibits147: F. Hoffmann La Roche Ltd. – Business segments
Exhibits148: F. Hoffmann La Roche Ltd. – Key news
Exhibits149: F. Hoffmann La Roche Ltd. – Key offerings
Exhibits150: F. Hoffmann La Roche Ltd. – Segment focus
Exhibits151: Jiangsu Hengrui Pharmaceuticals Co. Ltd. – Overview
Exhibits152: Jiangsu Hengrui Pharmaceuticals Co. Ltd. – Product / Service
Exhibits153: Jiangsu Hengrui Pharmaceuticals Co. Ltd. – Key offerings
Exhibits154: Johnson and Johnson – Overview
Exhibits155: Johnson and Johnson – Business segments
Exhibits156: Johnson and Johnson – Key news
Exhibits157: Johnson and Johnson – Key offerings
Exhibits158: Johnson and Johnson – Segment focus
Exhibits159: Novartis AG – Overview
Exhibits160: Novartis AG – Business segments
Exhibits161: Novartis AG – Key offerings
Exhibits162: Novartis AG – Segment focus
Exhibits163: Otsuka Holdings Co. Ltd. – Overview
Exhibits164: Otsuka Holdings Co. Ltd. – Business segments
Exhibits165: Otsuka Holdings Co. Ltd. – Key offerings
Exhibits166: Otsuka Holdings Co. Ltd. – Segment focus
Exhibits167: Pfizer Inc. – Overview
Exhibits168: Pfizer Inc. – Product / Service
Exhibits169: Pfizer Inc. – Key news
Exhibits170: Pfizer Inc. – Key offerings
Exhibits171: Puma Biotechnology Inc. – Overview
Exhibits172: Puma Biotechnology Inc. – Product / Service
Exhibits173: Puma Biotechnology Inc. – Key offerings
Exhibits174: Takeda Pharmaceutical Co. Ltd. – Overview
Exhibits175: Takeda Pharmaceutical Co. Ltd. – Product / Service
Exhibits176: Takeda Pharmaceutical Co. Ltd. – Key news
Exhibits177: Takeda Pharmaceutical Co. Ltd. – Key offerings
Exhibits178: Inclusions checklist
Exhibits179: Exclusions checklist
Exhibits180: Currency conversion rates for US$
Exhibits181: Research methodology
Exhibits182: Validation techniques employed for market sizing
Exhibits183: Information sources
Exhibits184: List of abbreviations



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/



※注目の調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(IRTNTR72701-23 )"上皮成長因子受容体(EGFR)阻害剤の世界市場2024~2028" (英文:Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market 2024-2028)はTechnavio社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。